Показано 0 из 0
Дата |
---|
17.08.2021 |
16.08.2021 |
13.08.2021 |
12.08.2021 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
|
|
5.57
|
5.55
|
5.65
|
5.64
|
|
|
|
|
|
|
5.63
|
5.51
|
5.70
|
5.51
|
|
|
341.40
|
|
|
|
5.74
|
5.63
|
5.75
|
5.63
|
|
|
|
|
|
|
5.48
|
5.48
|
5.74
|
5.62
|
|
|
|
|
4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs. The company’s drugs are intended to provide patients with various treatment options. Its pipeline is protected by a portfolio of patents and comprises three principal drug candidates that are in various stages of development.